Aripiprazole-induced adverse metabolic alterations in polyI:C
neurodevelopmental model of schizophrenia in rats

J 2017

Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats

HORSKÁ, Kateřina, Jana RUDÁ, Eva DRAŽANOVÁ, Michal KARPISEK, Regina DEMLOVÁ et. al.

Základní údaje

Originální název

Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats

Autoři

HORSKÁ, Kateřina (203 Česká republika), Jana RUDÁ (203 Česká republika, garant, domácí), Eva DRAŽANOVÁ (203 Česká republika, domácí), Michal KARPISEK (203 Česká republika), Regina DEMLOVÁ (203 Česká republika, domácí), Tomáš KAŠPÁREK (203 Česká republika, domácí) a Hana KOTOLOVÁ (203 Česká republika)

Vydání

Neuropharmacology, Oxford, Pergamon-Elsevier Science LTD, 2017, 0028-3908

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.249

Kód RIV

RIV/00216224:14110/17:00097232

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.neuropharm.2017.06.003

UT WoS

000406987300014

Klíčová slova anglicky

Adipokine; Aripiprazole; Leptin; Lipid profile; PolyI:C; Schizophrenia Wistar rats

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 27. 1. 2021 14:41, Mgr. Tereza Miškechová

Anotace

V originále

Schizophrenia appears to be linked to higher incidence of metabolic syndrome even in the absence of antipsychotic treatment. Atypical antipsychotics substantially differ in their propensity to induce metabolic alterations. Aripiprazole is considered to represent an antipsychotic drug with low risk of metabolic syndrome development. The aim of this study was to evaluate metabolic phenotype of neurodevelopmental polyI:C rat model and assess metabolic effects of chronic aripiprazole treatment with regard to complex neuroendocrine regulations of energy homeostasis. Polyinosinic:polycytidylic acid (polyI:C) was administered subcutaneously at a dose of 8 mg/kg in 10 ml on gestational day 15 to female Wistar rats. For this study 20 polyI:C and 20 control adult male offspring were used, randomly divided into 2 groups per 10 animals for chronic aripiprazole treatment and vehicle. Aripiprazole (5 mg/kg, dissolved tablets, ABILIFY®) was administered once daily via oral gavage for a month. Altered lipid profile in polyI:C model was observed and a trend towards different dynamics of weight gain in polyI:C rats was noted in the absence of significant antipsychotic treatment effect. PolyI:C model was not associated with changes in other parameters i.e. adipokines, gastrointestinal hormones and cytokines levels. Aripiprazole did not influence body weight but it induced alterations in neurohumoral regulations. Leptin and GLP-1 serum levels were significantly reduced, while ghrelin level was elevated. Furthermore aripiprazole decreased serum levels of pro-inflammatory cytokines. Our data indicate dysregulation of adipokines and gastrointestinal hormones present after chronic treatment with aripiprazole which is considered metabolically neutral in the polyI:C model of schizophrenia.

Návaznosti

LM2015090, projekt VaV

Název: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Akronym: CZECRIN)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN - Český národní uzel Evropské sítě infrastruktur klinického výzkumu

MUNI/A/1063/2016, interní kód MU

Název: Experimentální a translační farmakologický výzkum a vývoj

Investor: Masarykova univerzita, Experimentální a translační farmakologický výzkum a vývoj, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

Citovat

HORSKÁ, Kateřina, Jana RUDÁ, Eva DRAŽANOVÁ, Michal KARPISEK, Regina DEMLOVÁ, Tomáš KAŠPÁREK a Hana KOTOLOVÁ. Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats. Neuropharmacology. Oxford: Pergamon-Elsevier Science LTD, 2017, roč. 123, 1 September 2017, s. 148-158. ISSN 0028-3908. Dostupné z: https://dx.doi.org/10.1016/j.neuropharm.2017.06.003.

@article{1386067,
   author = {Horská, Kateřina and Rudá, Jana and Dražanová, Eva and Karpisek, Michal and Demlová, Regina and Kašpárek, Tomáš and Kotolová, Hana},
   article_location = {Oxford},
   article_number = {1 September 2017},
   doi = {http://dx.doi.org/10.1016/j.neuropharm.2017.06.003},
   keywords = {Adipokine; Aripiprazole; Leptin; Lipid profile; PolyI:C; Schizophrenia Wistar rats},
   language = {eng},
   issn = {0028-3908},
   journal = {Neuropharmacology},
   title = {Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats},
   url = {https://www.sciencedirect.com/science/article/pii/S0028390817302733?via%3Dihub},
   volume = {123},
   year = {2017}
}

TY  - JOUR
ID  - 1386067
AU  - Horská, Kateřina - Rudá, Jana - Dražanová, Eva - Karpisek, Michal - Demlová, Regina - Kašpárek, Tomáš - Kotolová, Hana
PY  - 2017
TI  - Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats
JF  - Neuropharmacology
VL  - 123
IS  - 1 September 2017
SP  - 148-158
EP  - 148-158
PB  - Pergamon-Elsevier Science LTD
SN  - 00283908
KW  - Adipokine
KW  - Aripiprazole
KW  - Leptin
KW  - Lipid profile
KW  - PolyI:C
KW  - Schizophrenia Wistar rats
UR  - https://www.sciencedirect.com/science/article/pii/S0028390817302733?via%3Dihub
L2  - https://www.sciencedirect.com/science/article/pii/S0028390817302733?via%3Dihub
N2  - Schizophrenia appears to be linked to higher incidence of metabolic syndrome even in the absence of antipsychotic treatment. Atypical antipsychotics substantially differ in their propensity to induce metabolic alterations. Aripiprazole is considered to represent an antipsychotic drug with low risk of metabolic syndrome development. The aim of this study was to evaluate metabolic phenotype of neurodevelopmental polyI:C rat model and assess metabolic effects of chronic aripiprazole treatment with regard to complex neuroendocrine regulations of energy homeostasis. Polyinosinic:polycytidylic acid (polyI:C) was administered subcutaneously at a dose of 8 mg/kg in 10 ml on gestational day 15 to female Wistar rats. For this study 20 polyI:C and 20 control adult male offspring were used, randomly divided into 2 groups per 10 animals for chronic aripiprazole treatment and vehicle. Aripiprazole (5 mg/kg, dissolved tablets, ABILIFY®) was administered once daily via oral gavage for a month. Altered lipid profile in polyI:C model was observed and a trend towards different dynamics of weight gain in polyI:C rats was noted in the absence of significant antipsychotic treatment effect. PolyI:C model was not associated with changes in other parameters i.e. adipokines, gastrointestinal hormones and cytokines levels. Aripiprazole did not influence body weight but it induced alterations in neurohumoral regulations. Leptin and GLP-1 serum levels were significantly reduced, while ghrelin level was elevated. Furthermore aripiprazole decreased serum levels of pro-inflammatory cytokines. Our data indicate dysregulation of adipokines and gastrointestinal hormones present after chronic treatment with aripiprazole which is considered metabolically neutral in the polyI:C model of schizophrenia.
ER  -

HORSKÁ, Kateřina, Jana RUDÁ, Eva DRAŽANOVÁ, Michal KARPISEK, Regina DEMLOVÁ, Tomáš KAŠPÁREK a Hana KOTOLOVÁ. Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats. \textit{Neuropharmacology}. Oxford: Pergamon-Elsevier Science LTD, 2017, roč.~123, 1 September 2017, s.~148-158. ISSN~0028-3908. Dostupné z: https://dx.doi.org/10.1016/j.neuropharm.2017.06.003.

Podrobný výpis o publikaci